July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases
Author Affiliations & Notes
  • Amina Rezkallah
    Ophthalmology, Croix Rousse Hospital, Lyon, France
  • Thibaud Mathis
    Ophthalmology, Croix Rousse Hospital, Lyon, France
  • Philippe Denis
    Ophthalmology, Croix Rousse Hospital, Lyon, France
  • Laurent Kodjikian
    Ophthalmology, Croix Rousse Hospital, Lyon, France
  • Footnotes
    Commercial Relationships   Amina Rezkallah, Allergan (R); Thibaud Mathis, None; Philippe Denis, Allergan (C); Laurent Kodjikian, Allergan (C)
  • Footnotes
    Support  Grants from Allergan
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3736. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amina Rezkallah, Thibaud Mathis, Philippe Denis, Laurent Kodjikian; XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3736. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal injections (IVI) of slow-release dexamethasone (DEX) are generally well tolerated. Ocular hypertension (OHT) and cataracts are the most common adverse effects of DEX-implant (DEX-I). The cases reported concern 5 eyes in four DEX-I IVI high-responder patients whose intraocular pressure (IOP) returned to normal after administration of a XEN gel stent with mitomycin subconjunctival injection

Methods : We reported the cases of 5 eyes in four DEX-I IVI high-responder patients whose intraocular pressure (IOP) returned to normal after administration of a XEN gel stent with mitomycin subconjunctival injection, thus allowing the continued use of DEX-I which was the only therapeutic option for these patients. All patients were pure steroid responders with normal optic nerves.

Results : No hypertension was observed in any of the eyes after DEX-implant intravitreal reinjection following XEN-surgery. All patients were successfully treated with XEN surgery and were retreated with DEX-implant with no further increase in IOP. The mean duration of follow-up after the MIGS procedure was 5 months (min-max, 2-12). None of the patients required needling.

Conclusions : XEN gel stent would seem to represent a safe and effective solution for treating steroid-induced hypertension. It allows for the medium and long-term use of DEX-I in high responders. It could be of clinical interest to study this combination in a prospective trial with a large number of patients and long-term follow-up.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×